Anthrax vaccine formulation and uses thereof

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9616117
APP PUB NO 20110236425A1
SERIAL NO

12998245

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

An anthrax vaccine with alhydrogel as the adjuvant is presented in a composition formulated by mixing rPA with colloidal alhydrogel (alum) adjuvant to produce the final product, comprising 200 μg/ml rPA bound to 0.26% alhydrogel in phosphate buffered saline (PBS), said formulation containing an optimal concentration of phosphate. Methods of using the vaccines to treat or prevent infections are also presented.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • PHARMATHENE, INC.

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Watkinson, Allan Guisborough, GB 13 166
Wilson, Robert Cumbernauld, GB 168 2386
Woodhouse, David Yarm, GB 212 2413

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Oct 11, 2024
11.5 Year Payment $7400.00 $3700.00 $1850.00 Oct 11, 2028
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00